A randomized Phase II study presented today at the International Association for the Study of Lung Cancer’s 13th World Conference of Lung Cancer (WCLC) compared the integrin inhibitor cilengitide and docetaxel in 2nd-line therapy for patients with stage IV non-small cell lung cancer (NSCLC).1 The data support the clinical program of Merck Serono, a division of Merck KGaA, Darmstadt, Germany, for the ongoing development of cilengitide in NSCLC.